BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served as chief development officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- EOG, GitLab, StoneCo, Cipher, BioCryst Insider Shake-Up
- 3 Best Value Stocks with Over 20% Upside in 2026, According to Analysts
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst price target raised to $22 from $21 at Wedbush
- Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value